JBIO

+ Watchlist + Portfolio

Jade Biosciences, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.77
52-Week Range: $8.36 – $28.00
Market Cap: $898.00M
P/E (TTM): —
EPS (TTM): -1.92
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.04
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 14.93
Debt/Equity: 0.00
Total Debt: $1.39M
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $438.18M

JBIO Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Research & Development	$93.12M
Selling, General & Admin	$20.42M
Operating Expenses	$113.54M
Operating Income	-$113.54M
EBITDA	-$113.52M
Pretax Income	-$127.35M
Income Tax	$58.00K
Net Income	-$127.41M
Diluted EPS	-3.19
Diluted Shares	31.36M

JBIO Cash Flow statement, annual periods, in USD
USD	FY2025
Operating Cash Flow	-$94.69M
Capital Expenditure	-$196.00K
Free Cash Flow	-$94.89M
Depreciation & Amortisation	$26.00K
Stock-Based Compensation	$20.01M
Investing Cash Flow	-$247.01M
Financing Cash Flow	$360.77M
Net Change in Cash	$19.07M

JBIO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$20.02M	$22.55M	$22.01M	$28.54M	$36.05M	$50.06M
Selling, General & Admin	$3.36M	$5.23M	$5.39M	$6.44M	$7.39M	$8.85M
Operating Expenses	$23.38M	$27.78M	$27.40M	$34.98M	$43.45M	$58.92M
Operating Income	-$23.38M	-$27.78M	-$27.40M	-$34.98M	-$43.45M	-$58.92M
EBITDA	-$23.38M	-$27.77M	-$27.39M	-$34.97M	-$43.44M	-$58.91M
Pretax Income	-$38.17M	-$32.13M	-$25.18M	-$31.87M	-$40.35M	-$55.75M
Income Tax	$0.00	$0.00	—	—	$16.00K	$15.00K
Net Income	-$38.17M	-$32.13M	-$25.18M	-$31.93M	-$40.37M	-$55.77M
Diluted EPS	-1.18	-0.86	-0.48	—	-0.57	-0.76
Diluted Shares	32.24M	28.44M	39.58M	—	57.78M	61.06M

JBIO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	—	$220.94M	$50.11M	$88.44M	$55.09M	$107.25M
Current Assets	—	$222.98M	$201.36M	$348.82M	$318.52M	$471.25M
Total Assets	—	$223.97M	$202.45M	$349.78M	$319.43M	$472.11M
Current Liabilities	—	$21.62M	$22.36M	$16.54M	$22.29M	$31.57M
Total Debt	—	$792.00K	$747.00K	$724.00K	$679.00K	$628.00K
Total Liabilities	—	$22.41M	$23.10M	$17.26M	$22.97M	$32.20M
Retained Earnings	—	-$117.28M	-$142.46M	-$174.39M	-$214.76M	-$270.52M
Shareholders' Equity	—	$201.56M	$179.35M	$332.52M	$296.46M	$439.92M
Working Capital	—	$201.36M	$179.00M	$332.28M	$296.23M	$439.68M

JBIO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$18.76M	-$20.16M	-$22.12M	-$33.65M	-$24.08M	-$43.66M
Capital Expenditure	—	—	-$57.00K	-$3.00K	—	—
Free Cash Flow	-$18.76M	-$20.30M	-$22.18M	-$33.65M	-$24.08M	-$43.66M
Depreciation & Amortisation	$0.00	$5.00K	$12.00K	$9.00K	$9.00K	$9.00K
Stock-Based Compensation	$2.42M	$3.90M	$4.29M	$9.40M	$7.41M	$13.61M
Investing Cash Flow	$0.00	-$136.00K	-$148.71M	-$98.16M	-$8.47M	-$97.63M
Financing Cash Flow	-$700.00K	$191.31M	$0.00	$170.16M	-$795.00K	$193.52M
Net Change in Cash	-$19.46M	$171.01M	-$170.83M	$38.35M	-$33.35M	$52.23M

Market Snapshot

About

Jade Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for metabolic and liver diseases. The company utilizes its proprietary drug discovery platforms to identify novel targets and develop small molecule and biological therapies. Jade is advancing a pipeline of product candidates addressing conditions including non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated liver disease, and related metabolic disorders. The company employs advanced screening technologies and translational research to accelerate drug development.